{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:17:54Z","timestamp":1786119474627,"version":"build-2736575974"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1097\/wnf.0b013e3181d47863","type":"journal-article","created":{"date-parts":[[2010,5,25]],"date-time":"2010-05-25T14:02:31Z","timestamp":1274796151000},"page":"129-134","source":"Crossref","is-referenced-by-count":11,"title":["Early Outcome of Acute Ischemic Stroke in Hyperlipidemic Patients Under Atorvastatin Versus Simvastatin"],"prefix":"10.1097","volume":"33","author":[{"given":"Yair","family":"Lampl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mordechai","family":"Lorberboym","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronit","family":"Gilad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Vysberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adele","family":"Tikozky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menachem","family":"Sadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Boaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"6","key":"R1-5-20210203","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa061894","article-title":"3rd, et al. Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack.","volume":"355","author":"Amarenceo","year":"2006","journal-title":"N Engl J Med"},{"issue":"12","key":"R2-5-20210203","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1161\/STROKEAHA.107.493106","article-title":"SPARCL Investigators. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.","volume":"38","author":"Amarenco","year":"2007","journal-title":"Stroke"},{"issue":"9","key":"R3-5-20210203","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1161\/STROKEAHA.107.513747","article-title":"SPARCL Investigators. Relative effects of statin therapy on stroke and cardiovascular events in men and women: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.","volume":"39","author":"Goldstein","year":"2008","journal-title":"Stroke"},{"issue":"35","key":"R4-5-20210203","doi-asserted-by":"crossref","first-page":"11104","DOI":"10.1523\/JNEUROSCI.23-35-11104.2003","article-title":"3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors protect cortical neurons from excitotoxicity.","volume":"23","author":"Zacco","year":"2003","journal-title":"J Neurosci"},{"issue":"4","key":"R5-5-20210203","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1161\/STROKEAHA.107.498923","article-title":"Simvastatin reduces the association of NMDA receptors to lipid rafts: a cholesterol-mediated effect in neuroprotection.","volume":"39","author":"Ponce","year":"2008","journal-title":"Stroke"},{"issue":"6","key":"R6-5-20210203","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/sj.jcbfm.9600227","article-title":"Atorvastatin downregulates tissue plasminogen activator-aggravated genes mediating coagulation and vascular permeability in single cerebral endothelial cells captured by laser microdissection.","volume":"26","author":"Liu","year":"2006","journal-title":"J Cereb Blood Flow Metab"},{"issue":"6","key":"R7-5-20210203","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/sj.jcbfm.9600070","article-title":"Protective effects of statins involving both eNOS and tPA in focal cerebral ischemia.","volume":"25","author":"Asahi","year":"2005","journal-title":"J Cereb Blood Flow Metab"},{"key":"R8-5-20210203","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.brainres.2007.07.012","article-title":"Effects of long-term administration of HMG-CoA reductase inhibitor, atorvastatin, on stroke events and local cerebral blood flow in stroke-prone spontaneously hypertensive rats.","volume":"1169","author":"Tanaka","year":"2007","journal-title":"Brain Res"},{"issue":"10","key":"R9-5-20210203","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1161\/01.STR.0000239659.99112.fb","article-title":"Influence of atorvastatin treatment on l-arginine cerebrovascular reactivity and flow-mediated dilatation in patients and lacunar infarctions.","volume":"37","author":"Pretnar-Obliak","year":"2006","journal-title":"Stroke"},{"issue":"4","key":"R10-5-20210203","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1074\/jbc.M707442200","article-title":"A pivotal role for interleukin-4 in atorvastatin-associated neuroprotection in rat brain.","volume":"283","author":"Clarke","year":"2008","journal-title":"J Biol Chem"},{"issue":"2","key":"R11-5-20210203","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.brainres.2005.02.044","article-title":"Effects of atorvastatin on blood-brain barrier permeability during l-NAME hypertension followed by angiotensin-II in rats.","volume":"1042","author":"Kalayci","year":"2005","journal-title":"Brain Res"},{"issue":"11","key":"R12-5-20210203","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1161\/STROKEAHA.107.489765","article-title":"NADPH oxidase plays a central role in blood-brain barrier damage in experimental stroke.","volume":"38","author":"Kahles","year":"2007","journal-title":"Stroke"},{"issue":"11","key":"R13-5-20210203","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1161\/ATVBAHA.107.150748","article-title":"The PI3K\/Akt pathway mediates the neuroprotection effect atorvastatin in extending thrombolytic therapy after embolic stroke in the rat.","volume":"27","author":"Zhang","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"R14-5-20210203","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/sj.jcbfm.9600034","article-title":"Atorvastatin induction of VEGF and BDNF promotes brain plasticity after stroke in mice.","volume":"25","author":"Chen","year":"2005","journal-title":"J Cereb Blood Flow Metab"},{"issue":"2","key":"R15-5-20210203","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.brainres.2005.06.004","article-title":"Long-term protective effect of atorvastatin in permanent focal cerebral ischemia.","volume":"1052","author":"Yrjanheikki","year":"2005","journal-title":"Brain Res"},{"issue":"5","key":"R16-5-20210203","doi-asserted-by":"crossref","first-page":"H2210","DOI":"10.1152\/ajpheart.01270.2005","article-title":"Atorvastatin protects cerebral infarction via inhibition of NADPH oxidase-derived superoxide in ischemic stroke.","volume":"291","author":"Hong","year":"2006","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"10","key":"R17-5-20210203","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1161\/01.STR.31.10.2442","article-title":"Atorvastatin upregulates type III nitric oxidase synthase in thrombocytes, decreases platelet activation and protects from cerebral ischemia in normocholesterolemic mice.","volume":"31","author":"Laufs","year":"2000","journal-title":"Stroke"},{"issue":"1-2","key":"R18-5-20210203","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jns.2008.07.029","article-title":"Atorvastatin enhances hypothermia-induced neuroprotection after stroke.","volume":"275","author":"Lee","year":"2008","journal-title":"J Neurol Sci"},{"issue":"2","key":"R19-5-20210203","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1161\/01.STR.0000054055.28435.BF","article-title":"Withdrawal of statin treatment abrogates stroke protection in mice.","volume":"34","author":"Gertz","year":"2003","journal-title":"Stroke"},{"issue":"19","key":"R20-5-20210203","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults.","volume":"285","year":"2001","journal-title":"JAMA"},{"issue":"19","key":"R21-5-20210203","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.106.174516","article-title":"AHA\/ACC; National Heart, Lung, and Blood Institute. AHA\/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute.","volume":"113","author":"Smith","year":"2006","journal-title":"Circulation"},{"issue":"8","key":"R22-5-20210203","first-page":"1024","article-title":"American College of Cardiology, American Heart Association, National Heart, Lung, and Blood Institute. ACC\/AHA\/NHLBI clinical advisory on the use and safety of statins.","volume":"106","author":"Pasternak","year":"2002","journal-title":"Circulation"},{"issue":"4","key":"R23-5-20210203","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1161\/01.STR.0000163257.66207.2d","article-title":"Stroke Council of the American Heart Association, American Stroke Association. Guideline for the early management of patients with ischemic stroke: 2005 guidelines update a scientific statement from the Stroke Council of the American Heart Association\/American Stroke Association.","volume":"36","author":"Adams","year":"2005","journal-title":"Stroke"},{"issue":"10","key":"R24-5-20210203","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1161\/01.STR.27.10.1817","article-title":"Comparison of neurological scales and scoring systems for acute stroke prognosis.","volume":"27","author":"Muir","year":"1996","journal-title":"Stroke"},{"issue":"3","key":"R25-5-20210203","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1161\/str.23.3.438b","article-title":"Reliability of the modified Rankin Scale.","volume":"23","author":"Burn","year":"1992","journal-title":"Stroke"},{"issue":"5","key":"R26-5-20210203","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1161\/01.STR.32.5.1091","article-title":"Improving the reliability of stroke subgroup classification using the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) criteria.","volume":"32","author":"Goldstein","year":"2001","journal-title":"Stroke"},{"key":"R27-5-20210203","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein-cholesterol without the use of the preparation ultracentrifuge.","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin Chem"},{"issue":"3","key":"R28-5-20210203","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2165\/00023210-200418030-00003","article-title":"Short-term effect of low dose atorvastatin on haemorheological parameters, platelet aggregation and endothelial function in patients with cerebrovascular disease and hyperlipidemia.","volume":"18","author":"Szapary","year":"2004","journal-title":"CNS Drug"},{"issue":"9","key":"R29-5-20210203","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1212\/01.wnl.0000269789.09277.47","article-title":"Statin treatment withdrawal in ischemic stroke: a controlled randomized study.","volume":"69","author":"Blanco","year":"2007","journal-title":"Neurology"},{"issue":"11","key":"R30-5-20210203","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S1474-4422(07)70250-8","article-title":"FASTER Investigators. Fast Assessment of Stroke and Transient Ischemic Attack to Prevent Early Recurrence (FASTER): a randomized controlled pilot trial.","volume":"6","author":"Kennedy","year":"2007","journal-title":"Lancet Neurol"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/WNF.0b013e3181d47863","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:20:18Z","timestamp":1786040418000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002826-201005000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/wnf.0b013e3181d47863","relation":{},"ISSN":["0362-5664"],"issn-type":[{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2010,5]]}}}